Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
OncoSec Medical Incorporated was a clinical-stage biotechnology company pioneering the development of novel intratumoral immunotherapies. Their primary focus was on utilizing their proprietary technology to deliver DNA-based therapeutics directly into tumors, aiming to stimulate a patient's own immune system to target and eradicate cancer cells. The company's lead investigational therapy, TAVO™ (tavokinogene telseplasmid), involved the intratumoral delivery of a DNA plasmid encoding for interleukin-12 (IL-12), a potent naturally occurring anti-cancer protein, often combined with their electroporation device, a GENESIS or Apollo system, to enhance cellular uptake. OncoSec concentrated on addressing unmet medical needs in oncology, particularly in difficult-to-treat cancers like metastatic melanoma and triple-negative breast cancer. In early 2024, OncoSec Medical Inc. completed a merger with Adgero Biopharmaceuticals Holdings, Inc., with the combined entity operating as Adgero Biopharmaceuticals Holdings, Inc.
Served as the central hub for corporate administration, clinical development oversight, research collaborations, and strategic planning for its immunotherapy programs.
The facility likely comprised modern office spaces and potentially access to or coordination with lab facilities suitable for a biotechnology company focused on clinical development.
As a clinical-stage biotech, the work culture was likely dynamic, science-driven, and highly collaborative, with a strong emphasis on innovation, research integrity, and the mission to develop impactful cancer therapies.
The Pennington headquarters was critical for managing OncoSec's clinical trials, R&D pipeline progression, investor relations, and regulatory interactions in the US.
While primarily US-based in its physical operations, OncoSec Medical Inc. had a global reach through its clinical trials conducted at various international sites, collaborations with global research institutions, and presentations at international scientific conferences. Its drug development programs aimed to address cancer, a global health issue.
24 N. Main Street
Pennington
New Jersey
USA
Address: Not consistently listed post-Pennington focus; previously had a significant presence.
Supported early-stage research, discovery, and potentially some clinical operations in the Western US.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, OncoSec' leadership includes:
OncoSec has been backed by several prominent investors over the years, including:
The most significant recent executive event was the merger with Adgero Biopharmaceuticals in early 2024, which effectively restructured the leadership. Prior to that, key appointments shaped OncoSec's late-stage clinical development.
Discover the tools OncoSec uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
OncoSec Medical Inc. likely utilized common corporate email formats, often combining first initial and last name.
[first_initial][last]@oncosec.com
Format
rarch@oncosec.com
Example
70%
Success rate
GlobeNewswire • February 7, 2024
OncoSec Medical Incorporated announced the completion of its previously announced merger with Adgero Biopharmaceuticals Holdings, Inc. The combined company will operate under the name Adgero Biopharmaceuticals Holdings, Inc. and its common stock will trade on the Nasdaq Capital Market under the ticker symbol 'ADGE'....more
GlobeNewswire • March 20, 2023
OncoSec Medical Incorporated announced the appointment of Robert (Bob) H. Arch as President and Chief Executive Officer and a member of the Board of Directors, effective March 20, 2023....more
GlobeNewswire • December 12, 2022
OncoSec presented promising interim data from its Phase 2b KEYNOTE-695 trial evaluating TAVO™ in combination with KEYTRUDA® (pembrolizumab) in patients with anti-PD-1 checkpoint refractory metastatic melanoma. The data showed clinically meaningful and durable responses....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including OncoSec, are just a search away.